An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia

Summary

A randomized, double-blind, placebo-controlled parallel group 3-arm study assessing efficacy, safety, and tolerability of two doses BXCL501 in male and female geriatric residents (65 years and older) with acute agitation associated with all forms of dementia (i.e., probably Alzheimer's Disease, vascular dementia; mixed; frontotemporal dementia) excluding Parkinson's-Related Dementia and Lewy Body Dementia.

Timeline

Start

2022-02-08

Primary completion

2022-04-01

Completion

2022-04-01

Drugs

Indications